New Approaches in HLA Matching – HLA Matchmaker

Written by Dr. Libor Kolesár (Senior Field Applications Scientist, Omixon)   Introduction Most transplant laboratories’ protocols for donor/patient matching are based on the number of mismatches between patient and donor HLA alleles/antigens. The fewer mismatches between two individuals, the better. In solid organ transplantation (SOT) minimum matching refers to...

 

Read more

Mortality Prediction Hidden in our Genome

The success of hematopoietic stem cell transplant (HSCT) is influenced by many factors including HLA mismatches, variations in the major histocompatibility complex (MHC) region, minor histocompatibility targets of allorecognition, regulatory elements that affect gene expression and genetic variation that affects immune responses (Table 1, Table 2). The individual contribution...

 

Read more

Omixon to Sponsor EWIC 2019 Conference with Scientific Talk

Omixon is proud to announce that we are one of the Silver Sponsors of the Annual EWIC 2019 Conference. Libor Kolesár (Senior Field Application Scientist) and Nina Lauterbach (Field Application Scientist) will announce improvements to the existing products and an interesting talk by Mette Christiansen from Aarhus University. Title of...

 

Read more

Omixon & PIRCHE® collaborate on Epitope Determination with NGS

Global molecular diagnostics company Omixon, headquartered in Budapest, and technology company PIRCHE AG, headquartered in Berlin announce a collaboration to deliver the first integrated epitope determination and matching service that leverages whole gene consensus sequences assembled from NGS data of the HLA region. For the first time, fully characterized...

 

Read more